Osteopathology of the jaw associated with bone resorption inhibitors: what have we learned in the last 8 years? A single-centre experience with 110 patients
Osteopathology of the jaw associated with bone resorption inhibitors: what have we learned in the last 8 years? A single-centre experience with 110 patients
复制标题
DOI：
10.4414/smw.2012.13605
复制
发表时间：
2012-06-26
影响因子：
2.9
通讯作者：
Graetz, Klaus Wilhelm
中科院分区：
文献类型：
--
作者：
Jacobsen, Christine;Metzler, Philipp;Graetz, Klaus Wilhelm
研究中的问题：在发现与双膦酸盐治疗相关的颌骨骨坏死8年后，在治疗112例该疾病患者中获得了大量经验。这种疾病虽然不常见，但对患者和治疗专家来说仍然是一种负担，而且没有适当的标准化分类和治疗方法。本文介绍了收集的患者数据，积累的经验和相应的知识变化的总结，在诊断措施和治疗。方法：回顾性分析112例双膦酸盐相关颌骨病变特殊诊所患者的资料，并与文献资料进行比较。结果：共有110例患者被纳入数据分析，其中70%为女性。四分之一的患者以骨质疏松为基础疾病，超过一半的患者以拔牙为局部影响因素。四分之三的患者病变位于下颌骨，几乎所有患者均表现出感染的临床症状。总的来说，58%的患者接受了手术治疗，7年内完全缓解率为78%。结论：对患者资料和文献的总结表明，对双膦酸盐相关颌骨骨病的了解变得越来越具体。与这种疾病相关的药物范围已经增加，而且治疗选择也越来越成功。在发现BRONJ后不久发表的分类需要修订和纳入新的知识。
QUESTIONS UNDER STUDY: 8 years after discovery of osteonecrosis of the jaw associated with bisphosphonate therapy a lot of experience has been garnered in treating 112 patients with this disease. This disease, although uncommon, is still a burden for the patient as well as the treating specialists and an adequate standardised classification as well as therapy does not exist. This article presents a summary of collected patient data, garnered experience and consequential changes in knowledge, in diagnostic measures and therapy.METHODS: The data of in total 112 patients referred to the Special Clinics for patients with bisphosphonate-associated lesions of the jaw was retrospectively analysed and compared with data from the literature.RESULTS: In total, 110 patients, 70% women, were included in the data analysis. A quarter of those patients had osteoporosis as the underlying disease, more than half of all patients had extractions as the local influencing factor. The lesion was localised in the mandible in three quarters of all patients and almost all patients showed clinical signs of infection. In total, 58% of all patients were treated surgically with a complete remission rate of 78% over 7 years.CONCLUSIONS: This summary of patient data and literature shows that knowledge about bisphosphonate-associated osteopathology of the jaw becomes more and more specific. The range of drugs associated with this disease has increased, but also therapeutic options show more and more success. Classifications, published shortly after the discovery of BRONJ need to be revised and new knowledge included.